Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
Smith & Nephew plc, a global medical technology business, announced on May 1, 2025, that its total issued share capital as of April 30, 2025, comprises 877,710,150 ordinary shares, including 1,768,914 held in treasury. This results in 875,941,236 shares with voting rights, which shareholders should use as the denominator for notifying changes in their interest under FCA rules.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats receives a solid overall score of 77.0, driven by strong financial performance and positive earnings call sentiment. The company’s impressive revenue and profit growth, coupled with innovation-driven strategies, contribute to a favorable outlook. However, high valuation ratios and technical analysis indicators suggest caution. Challenges in the China market and input cost pressures in Orthopedics remain key risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
YTD Price Performance: 15.83%
Average Trading Volume: 877,848
Technical Sentiment Signal: Sell
Current Market Cap: $12.27B
See more insights into SNN stock on TipRanks’ Stock Analysis page.